Japanese Encephalitis - Pipeline Review, H2 2015

Publisher Name :
Date: 09-Dec-2015
No. of pages: 47
Inquire Before Buying

Global Markets Direct's, ‘Japanese Encephalitis - Pipeline Review, H2 2015', provides an overview of the Japanese Encephalitis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Japanese Encephalitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Japanese Encephalitis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Japanese Encephalitis

  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

  • The report reviews key players involved in the therapeutics development for Japanese Encephalitis and enlists all their major and minor projects

  • The report summarizes all the dormant and discontinued pipeline projects

  • A review of the Japanese Encephalitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

  • A detailed assessment of monotherapy and combination therapy pipeline projects

  • Coverage of the Japanese Encephalitis pipeline on the basis of target, MoA, route of administration and molecule type

  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

  • Develop strategic initiatives by understanding the focus areas of leading companies

  • Identify and understand important and diverse types of therapeutics under development for Japanese Encephalitis

  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

  • Devise corrective measures for pipeline projects by understanding Japanese Encephalitis pipeline depth and focus of Indication therapeutics

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Japanese Encephalitis - Pipeline Review, H2 2015

Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Japanese Encephalitis Overview 7
Therapeutics Development 8
Pipeline Products for Japanese Encephalitis - Overview 8
Pipeline Products for Japanese Encephalitis - Comparative Analysis 9
Japanese Encephalitis - Therapeutics under Development by Companies 10
Japanese Encephalitis - Therapeutics under Investigation by Universities/Institutes 11
Japanese Encephalitis - Pipeline Products Glance 12
Late Stage Products 12
Early Stage Products 13
Unknown Stage Products 14
Japanese Encephalitis - Products under Development by Companies 15
Japanese Encephalitis - Products under Investigation by Universities/Institutes 16
Japanese Encephalitis - Companies Involved in Therapeutics Development 17
Indian Immunologicals Limited 17
Panacea Biotec Limited 18
Sanofi 19
Vaxine Pty Ltd 20
Zydus Cadila Healthcare Limited 21
Japanese Encephalitis - Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Target 23
Assessment by Mechanism of Action 24
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
encephalitis vaccine - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
FDX-000 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Japanese encephalitis vaccine - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Japanese encephalitis vaccine - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Japanese encephalitis vaccine - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Japanese encephalitis vaccine - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Japanese encephalitis vaccine - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Japanese encephalitis vaccine - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Japanese encephalitis vaccine - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Japanese encephalitis vaccine - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Japanese encephalitis vaccine - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Small Molecules to Inhibit NS5 for Japanese Encephalitis and Viral Infections - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Japanese Encephalitis - Recent Pipeline Updates 42
Japanese Encephalitis - Dormant Projects 43
Japanese Encephalitis - Discontinued Products 44
Japanese Encephalitis - Product Development Milestones 45
Featured News & Press Releases 45
Dec 10, 2012: Sanofi Pasteur Launches Imojev First Single-dose Vaccine Against Japanese Encephalitis In Australia 45
Jun 29, 2007: Discontinuation of Japanese encephalitis vaccine 45
Appendix 46
Methodology 46
Coverage 46
Secondary Research 46
Primary Research 46
Expert Panel Validation 46
Contact Us 46
Disclaimer 47

List of Tables

Number of Products under Development for Japanese Encephalitis, H2 2015 8
Number of Products under Development for Japanese Encephalitis - Comparative Analysis, H2 2015 9
Number of Products under Development by Companies, H2 2015 10
Number of Products under Investigation by Universities/Institutes, H2 2015 11
Comparative Analysis by Late Stage Development, H2 2015 12
Comparative Analysis by Early Stage Development, H2 2015 13
Comparative Analysis by Unknown Stage Development, H2 2015 14
Products under Development by Companies, H2 2015 15
Products under Investigation by Universities/Institutes, H2 2015 16
Japanese Encephalitis - Pipeline by Indian Immunologicals Limited, H2 2015 17
Japanese Encephalitis - Pipeline by Panacea Biotec Limited, H2 2015 18
Japanese Encephalitis - Pipeline by Sanofi, H2 2015 19
Japanese Encephalitis - Pipeline by Vaxine Pty Ltd, H2 2015 20
Japanese Encephalitis - Pipeline by Zydus Cadila Healthcare Limited, H2 2015 21
Assessment by Monotherapy Products, H2 2015 22
Number of Products by Stage and Target, H2 2015 23
Number of Products by Stage and Mechanism of Action, H2 2015 24
Number of Products by Stage and Route of Administration, H2 2015 26
Number of Products by Stage and Molecule Type, H2 2015 28
Japanese Encephalitis Therapeutics - Recent Pipeline Updates, H2 2015 42
Japanese Encephalitis - Dormant Projects, H2 2015 43
Japanese Encephalitis - Discontinued Products, H2 2015 44

List of Figures

Number of Products under Development for Japanese Encephalitis, H2 2015 8
Number of Products under Development for Japanese Encephalitis - Comparative Analysis, H2 2015 9
Number of Products under Development by Companies, H2 2015 10
Number of Products under Investigation by Universities/Institutes, H2 2015 11
Comparative Analysis by Early Stage Products, H2 2015 13
Assessment by Monotherapy Products, H2 2015 22
Number of Products by Routes of Administration, H2 2015 25
Number of Products by Stage and Routes of Administration, H2 2015 25
Number of Products by Molecule Types, H2 2015 27
Number of Products by Stage and Molecule Types, H2 2015 27
  • Global Varicose Vein Treatment Market Research Report 2017
    Published: 22-Jun-2017        Price: US 2900 Onwards        Pages: 112
    In this report, the global Varicose Vein Treatment market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Varicose Vein Treatment in these regions, from 2012 to 2022 (forecast), covering - North America - Europe - Ch......
  • Global Anti-inflammatory Therapeutics Market Research Report 2017
    Published: 21-Jun-2017        Price: US 2900 Onwards        Pages: 100
    In this report, the global Anti-inflammatory Therapeutics market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Anti-inflammatory Therapeutics in these regions, from 2012 to 2022 (forecast), covering - North America - Euro......
  • EMEA (Europe, Middle East and Africa) Brachytherapy Afterloaders, Brachytherapy Seeds Market Report 2017
    Published: 14-Jun-2017        Price: US 4000 Onwards        Pages: 107
    In this report, the EMEA Brachytherapy Afterloaders, Brachytherapy Seeds market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split EMEA into Europe, the Middle East and Africa, With sales (K Units), revenue (Million USD), market share and growth rate of Brachytherapy Afterloaders, Brachytherapy Seeds for these regions, from 2012 to 2022 (forecast) -......
  • Global Anti-inflammatory Therapeutics Market 2017-2021
    Published: 14-Jun-2017        Price: US 3500 Onwards        Pages: 98
    Inflammation is a part of immune response triggered against harmful stimuli, foreign objects, damaged cells, irritants, and pathogens in the body. The drugs used to treat these symptoms are called anti-inflammatory drugs. It causes the elimination of the initial cause of cell injury, clearance of dead or necrotic cells, and damaged tissue from the site of the inflammatory process and initiates tissue repair. The analysts forecast global anti-inflammatory therapeutics market to grow at......
  • Global Substance Abuse Treatment Market 2017-2021
    Published: 14-Jun-2017        Price: US 3500 Onwards        Pages: 73
    Substance abuse is defined as an illicit use of alcohol, drugs, or cigarettes. They are potentially addictive in nature, difficult to treat, and have a negative impact on body and overall health. The major factors driving the market is the increase in substance usage and the number of associated deaths. It is also identified as a high economic burden. Substance abuse is one of the primary causes of death globally and a major economic burden. Substance abuse, along with addiction is associated......
  • United States Varicose Vein Treatment Market by Manufacturers, States, Type and Application, Forecast to 2022
    Published: 13-Jun-2017        Price: US 4480 Onwards        Pages: 118
    There are several treatment options for Varicose Veins, wearing support stockings, Varicose Vein Treatment Devices; endogenous laser treatment, radiofrequency occlusion, surgery, and lasers and intense pulsed light. Mentioning medical devices for treating Varicose Veins, there is mainly Laser devices, Trivex and RFITT system. Scope of the Report: This report focuses on the Varicose Vein Treatment in United States market, to split the market based on manufacturers, states, ......
  • Metachromatic Leukodystrophy (MLD) - Pipeline Review, H1 2017
    Published: 13-Jun-2017        Price: US 2000 Onwards        Pages: 35
    Metachromatic Leukodystrophy (MLD) - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Metachromatic Leukodystrophy (MLD) - Pipeline Review, H1 2017, provides an overview of the Metachromatic Leukodystrophy (MLD) (Central Nervous System) pipeline landscape. Metachromatic leukodystrophy is an inherited disorder characterized by the accumulation of fats called sulfatides in cells. Symptoms......
  • Canavan Disease - Pipeline Review, H1 2017
    Published: 13-Jun-2017        Price: US 2000 Onwards        Pages: 25
    Canavan Disease - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Canavan Disease - Pipeline Review, H1 2017, provides an overview of the Canavan Disease (Central Nervous System) pipeline landscape. Canavan disease is a gene-linked neurological disorder in which the brain degenerates into spongy tissue riddled with microscopic fluid-filled spaces. Cause includes a mutation in the gene ......
  • Globoid Cell Leukodystrophy (Krabbe Disease) - Pipeline Review, H1 2017
    Published: 13-Jun-2017        Price: US 2000 Onwards        Pages: 40
    Globoid Cell Leukodystrophy (Krabbe Disease) - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Globoid Cell Leukodystrophy (Krabbe Disease) - Pipeline Review, H1 2017, provides an overview of the Globoid Cell Leukodystrophy (Krabbe Disease) (Central Nervous System) pipeline landscape. Krabbe disease also called globoid cell leukodystrophy is a degenerative disorder caused by the defici......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs